HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials.
about
Mechanisms of resistance to anti-EGFR therapy in colorectal cancerHER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologistsThe role of MAPK signaling pathway in the Her-2-positive meningiomas.Comparing mutation calls in fixed tumour samples between the affymetrix OncoScan® array and PCR based next-generation sequencing.High levels of serum platelet-derived growth factor-AA and human epidermal growth factor receptor-2 are predictors of colorectal cancer liver metastasisComparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer.Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment.Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications.Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the piePlasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer.Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies.Recent developments in the treatment of metastatic colorectal cancer.Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial.Trastuzumab Plus Pertuzumab Resistance Does Not Preclude Response to Lapatinib Plus Trastuzumab in HER2-Amplified Colorectal Cancer.Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer.Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.Immunotherapy for Colorectal Cancer.Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer.Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells.
P2860
Q28074073-5984FA71-8851-4B2B-AC77-D31C7A2ED7C4Q28078111-0A87EA1C-A829-4C77-8AF4-72D6B9420A68Q33363315-32655CB5-0B23-4218-91A0-F4CD7211F2CFQ36313666-99209138-A500-43D6-840A-422995935D88Q37662632-E7EC5065-B595-4AFC-B193-D38C5A782934Q38648453-9D526314-29E5-432A-958B-17D6D110F519Q38679229-C679F783-FA8B-4183-8F36-317FEDE2C5C7Q38794338-52C6CBB1-4385-4B96-B5B7-2845D108ACCAQ39172118-1199618F-B147-4810-B932-AA0B1F0FEA4AQ39223563-8987C810-AFC0-4912-BCC7-F4FAF19E6531Q39453553-5908E57D-CDCE-4B35-962C-AD1D3778EF3CQ41105389-EE9B1E6A-6823-46AC-BE94-23E274C0131EQ47190268-604F72E7-9378-45D0-994C-BB89B478E9AFQ47560949-EB6AC7E9-09F4-44B2-A181-103663221478Q47707557-EA587DBB-6582-46C7-87F1-F54CAE75E4C8Q48234912-5302B8EA-1EE8-4C8A-8E58-84DD80304B38Q53111596-2A8637C8-6192-4F79-9A2F-16C38AAB425DQ54962247-F62239F6-3A11-441E-BF1F-A3B95413BC7DQ55411157-A86227BA-15D0-4529-88E0-510AB9B7765F
P2860
HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
HER2 overexpression and amplif ...... COLO colorectal cancer trials.
@ast
HER2 overexpression and amplif ...... COLO colorectal cancer trials.
@en
HER2 overexpression and amplif ...... COLO colorectal cancer trials.
@en-gb
type
label
HER2 overexpression and amplif ...... COLO colorectal cancer trials.
@ast
HER2 overexpression and amplif ...... COLO colorectal cancer trials.
@en
HER2 overexpression and amplif ...... COLO colorectal cancer trials.
@en-gb
prefLabel
HER2 overexpression and amplif ...... COLO colorectal cancer trials.
@ast
HER2 overexpression and amplif ...... COLO colorectal cancer trials.
@en
HER2 overexpression and amplif ...... COLO colorectal cancer trials.
@en-gb
P2093
P2860
P50
P921
P356
P6366
P1154
2-s2.0-84959228461
P1476
HER2 overexpression and amplif ...... COLO colorectal cancer trials.
@en
P2093
Assa Oumie
Debra Cross
Gemma Hemmings
Gordon Hutchins
Jennifer Barrett
Joseph M Foster
Karen G Spink
Marc Jones
Matthew Seymour
Morag Taylor
P2860
P304
P356
10.1002/PATH.4679
P5530
P577
2015-12-22T00:00:00Z
P5875
P6179
1032824872
P6366
2212171768